
CLAIMS

1. Use of a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof

wherein in formula (I):

R^2 , R^3 , R^5 ,independently from each other are C_1-C_6 alkyl,

R^1, R^4 , independently from each other are hydrogen or C_1-C_6 alkyl,

R^6 is C_1-C_6 alkyl, halo, C_1-C_6 alkoxy or C_1-C_6 haloalkyl,

n is 2-3

m is 1-3,

in the manufacturing of a medicament for the treatment of a condition requiring inotropic activity.

2. Use according to claim 1, wherein said medicament is free of side effects caused by increased calcium concentration.

3. Use according to claims 1-2, wherein R^4 is hydrogen.

4. Use according to claim 3, wherein n is 2.

5. Use according to claim 4, wherein R^2 is methyl.

6. Use according to claim 5, wherein the two R^2 groups are attached to the same carbon ring of the piperidine ring of formula (I), preferably in the 3-yl position.

7. Use according to claims 1-6, wherein one or more of the following conditions apply:

   - both R^3, and R^5 are C_1-C_3 alkyl, preferably methyl.
   - m is 3
   - R^6 is halo and/or alkoxy, preferably with at least one R^6 being alkoxy.

8. Use according to claims 1-7, wherein said compound of formula (I) is 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea.

9. Use according to claims 1-8, wherein said pharmaceutically acceptable salt is a monohydrochloride salt.

10. Use according to claims 1-9, wherein said condition is connected with a reduced and/or ineffective heart contractility.

11. Use according to claims 1-10, wherein said condition is selected from heart failure, heart attack, cardiogenic shock, septic shock, myocardial infarction, cardiomyopathy, pulmonary artery hypertension (PAH).

12. Use according to claim 11, wherein said cardiomyopathy is dilated cardiomyopathy (DCM), in particular, familial DCM.

13. Use according to claims 1-11, wherein said condition is severe, advanced, chronic or acute heart failure.

14. Use according to claims 1-11, wherein said condition is severe, advanced, chronic or acute heart failure with reduced heart ejection fraction.

15. Use according to claims 2-14, wherein said side effects due to increased calcium concentrations are selected from increased myocardial oxygen demand, ischemia, arrhythmia and hypotension.